Treatment and prophylaxis of pancreatitis

• US 5,753,681 A
• Filed: 03/17/1997
• Issued: 05/19/1998
• Est. Priority Date: 03/18/1996
• Status: Expired due to Fees

• Current Assignee: Sankyo Company Limited (Daiichi Sankyo Company Limited)
• Original Assignee: Sankyo Company Limited (Daiichi Sankyo Company Limited)
• Inventors: Fukami, Masaharu, Fujiwara, Toshihiko, Horikoshi, Hiroyoshi
• Primary Examiner(s): JORDAN, KIMBERLY R
• Application Number:
  US08/819,686
• Time in Patent Office: 428 Days
• Field of Search: 514/337, 514/369, 514/370
• US Class Current: 514/337
• CPC Class Codes: A61K 31/427 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/4439 containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole nicotine A61K31/465
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes

Abstract

Insulin sensitizers, especially thiazolidinedione compounds, such as troglitazone, are useful for the treatment and prevention of pancreatitis.

Claims

1. A method for the treatment or prophylaxis of pancreatitis by administering to a human suffering from or susceptible to pancreatitis an effective dose of an insulin sensitizer sufficient to treat or inhibit pancreatitis.

2. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of thiazolidinedione compounds, oxazolidinedione compounds, isoxazolidinedione compounds and oxadiazolidinedione compounds.

3. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of thiazolidinedione compounds and isoxazolidinedione compounds.

4. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of compounds of formula (I):

##STR4## wherein;

R¹ and R² are the same as or different from each other and each represents a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms;

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 6 carbon atoms, a cycloalkanecarbonyl group having from 5 to 7 carbon atoms in the cycloalkane part, a benzoyl group, a naphthoyl group, a benzoyl or naphthoyl group which is substituted by at least one substituent selected from the group consisting of substituents α

, defined below, a heterocyclic acyl group in which the heterocyclic part has from 4 to 7 ring atoms of which from 1 to 3 are hetero-atoms selected from the group consisting of nitrogen, oxygen and sulfur atoms, a phenylacetyl group, a phenylpropionyl group, a phenylacetyl or phenylpropionyl group which is substituted by at least one halogen substituent, a cinnamoyl group, an alkoxycarbonyl group having from 1 to 6 carbon atoms in the alkoxy part or a benzyloxycarbonyl group;

R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom, an alkyl group having from 1 to 5 carbon atoms or an alkoxy group having from 1 to 5 carbon atoms, or R⁴ and R⁵ together represent an alkylenedioxy group having from 1 to 4 carbon atoms;

n is 1,2or3;

Y and Z are the same as or different from each other and each represents an oxygen atom or an imino group; and

substituents α

are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, halogen atoms, hydroxy groups, amino groups, alkylamino groups having from 1 to 4 carbon atoms, dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, and nitro groups;

and pharmaceutically acceptable salts thereof.

5. The method of claim 4, wherein said insulin sensitizer is selected from the group consisting of compounds of formula (Ia):

##STR5## wherein;

R¹, R², R⁴ and R⁵ are the same as or different from each other and each represents a hydrogen atom or an alkyl group having from 1 to 5 carbon atoms; and

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 6 carbon atoms, a benzoyl group, a naphthoyl group, a benzoyl or naphthoyl group which is substituted by at least one substituent selected from the group consisting of substituents α

, defined below, or an alkoxycarbonyl group having from 1 to 6 carbon atoms in the alkoxy part;

substituents α

are selected from the group consisting of alkyl groups having from 1 to 4 carbon atoms, alkoxy groups having from 1 to 4 carbon atoms, halogen atoms, hydroxy groups, amino groups, alkylamino groups having from 1 to 4 carbon atoms, dialkylamino groups having from 1 to 4 carbon atoms in each alkyl part, and nitro groups;

and pharmaceutically acceptable salts thereof.

6. The method of claim 4, wherein R¹ represents an alkyl group having from 1 to 4 carbon atoms.

7. The method of claim 4, wherein R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

8. The method of claim 4, wherein R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxycarbonyl group having from 2 to 4 carbon atoms.

9. The method of claim 4, wherein R⁴ represents an alkyl group having from 1 to 4 carbon atoms.

10. The method of claim 4, wherein R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

11. The method of claim 4, wherein:

R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxycarbonyl group having from 2 to 4 carbon atoms;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

12. The method of claim 4, wherein R³ represents a hydrogen atom, an acetyI group, a benzoyl group or an ethoxycarbonyl group.

13. The method of claim 4, wherein:

R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

14. The method of claim 4, wherein R¹ represents a methyl group.

15. The method of claim 4, wherein R² represents a hydrogen atom or a methyl group.

16. The method of claim 4, wherein R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group.

17. The method of claim 4, wherein R⁴ represents a methyl or a t-butyl group.

18. The method of claim 4, wherein R⁵ represents a hydrogen atom or a methyl group.

19. The method of claim 4, wherein:

R¹ represents a methyl group;

R² represents a hydrogen atom or a methyl group;

R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group;

R⁴ represents a methyl or a t-butyl group; and

R⁵ represents a hydrogen atom or a methyl group.

20. The method of claim 5, wherein R¹ represents an alkyl group having from 1 to 4 carbon atoms.

21. The method of claim 5, wherein R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

22. The method of claim 5, wherein R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxycarbonyl group having from 2 to 4 carbon atoms.

23. The method of claim 5, wherein R⁴ represents an alkyl group having from 1 to 4 carbon atoms.

24. The method of claim 5, wherein R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

25. The method of claim 5, wherein:

R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

R³ represents a hydrogen atom, an aliphatic acyl group having from 1 to 4 carbon atoms, an unsubstituted benzoyl or naphthoyl group, or an alkoxycarbonyl group having from 2 to 4 carbon atoms;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

26. The method of claim 5, wherein R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group.

27. The method of claim 5, wherein:

R¹ represents an alkyl group having from 1 to 4 carbon atoms;

R² represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms;

R³ represents a hydrogen atom, an acetyl group, a benzoyl group or an ethoxycarbonyl group;

R⁴ represents an alkyl group having from 1 to 4 carbon atoms; and

R⁵ represents a hydrogen atom or an alkyl group having from 1 to 3 carbon atoms.

28. The method of claim 5, wherein R¹ represents a methyl group.

29. The method of claim 5, wherein R² represents a hydrogen atom or a methyl group.

30. The method of claim 5, wherein R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group.

31. The method of claim 5, wherein R⁴ represents a methyl or a t-butyl group.

32. The method of claim 5, wherein R⁵ represents a hydrogen atom or a methyl group.

33. The method of claim 5, wherein:

R¹ represents a methyl group;

R² represents a hydrogen atom or a methyl group;

R³ represents a hydrogen atom, an acetyl group or an ethoxycarbonyl group;

R⁴ represents a methyl or a t-butyl group; and

R⁵ represents a hydrogen atom or a methyl group.

34. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-hydroxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)-benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

35. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-hydroxy-2-methyl-7-t-butylchroman-2-ylmethoxy)-benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

36. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-hydroxy-2-ethyl-5,7,8-trimethylchroman-2-yl-methoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

37. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-hydroxy-2-isobutyl-5,7,8-trimethylchroman-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

38. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-acetoxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)-benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

39. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-ethoxycarbonyloxy-2,5,7,8-tetramethylchroman-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

40. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 6-(2-fluorobenzyloxy)-2-naphthylmethyl! thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

41. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-{4- 2-(5-ethylpyridin-2-yl)ethoxy!benzyl}thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

42. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-(2-benzyl-3,4-dihydro-2H-benzopyran-6-ylmethyl)-thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

43. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-{2- N-methyl-N-(pyridin-2-yl)amino!ethoxy}benzyl!-thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

44. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-(4-{2- 1-(4-2'"'"'-pyridylphenyl)ethylideneaminooxy!ethoxy}-benzyl)thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

45. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 4-{4- 2-(5-methyl-2-phenyloxazol-4-yl)ethoxy!benzyl}-isoxazolidine-3,5-dione and pharmaceutically acceptable salts thereof.

46. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-{4-(5-methoxy-3-methylimidazo 4,5-b!pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

47. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-{4-(5-methoxy-3-methylimidazo 4,5-b!pyridin-2-yl-methoxy)benzyl}thiazolidine-2,4-dione and its hydrochloride.

48. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(6-methoxy-1-methylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

49. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(1-methylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

50. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(5-hydroxy-1,4,6,7-tetramethylbenzimidazol-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

51. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5- 4-(1-methylindolin-2-ylmethoxy)benzyl!thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.

52. The method of claim 1, wherein said insulin sensitizer is selected from the group consisting of 5-{4- 3-(5-methyl-2-phenyloxazol-4-yl)propionyl!benzyl}thiazolidine-2,4-dione and pharmaceutically acceptable salts thereof.